Both genes have proven oncogenic effects, such as the role of acetylated STAT3-mediated activation of IGF2 transcription in HDI (Histone deacetylase inhibitors) resistance described in NSCLC (non-small-cell lung carcinoma) [76]. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.